BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 25340957)

  • 1. Stable and efficient transfection of siRNA for mutated KRAS silencing using novel hybrid nanoparticles.
    Lakshmikuttyamma A; Sun Y; Lu B; Undieh AS; Shoyele SA
    Mol Pharm; 2014 Dec; 11(12):4415-24. PubMed ID: 25340957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting KRAS Mutant Lung Cancer Cells with siRNA-Loaded Bovine Serum Albumin Nanoparticles.
    Mehta A; Dalle Vedove E; Isert L; Merkel OM
    Pharm Res; 2019 Jul; 36(9):133. PubMed ID: 31289919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective suppression of the Kirsten rat sarcoma viral oncogene in pancreatic tumor cells via targeted small interfering RNA delivery using nanoparticles.
    Zeng L; Li J; Li J; Zhang Q; Qian C; Wu W; Lin Z; Liang J; Chen Y; Huang K
    Pancreas; 2015 Mar; 44(2):250-9. PubMed ID: 25401377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced endosomal escape of siRNA-incorporating hybrid nanoparticles from calcium phosphate and PEG-block charge-conversional polymer for efficient gene knockdown with negligible cytotoxicity.
    Pittella F; Zhang M; Lee Y; Kim HJ; Tockary T; Osada K; Ishii T; Miyata K; Nishiyama N; Kataoka K
    Biomaterials; 2011 Apr; 32(11):3106-14. PubMed ID: 21272932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted nanoconjugate co-delivering siRNA and tyrosine kinase inhibitor to KRAS mutant NSCLC dissociates GAB1-SHP2 post oncogene knockdown.
    Srikar R; Suresh D; Zambre A; Taylor K; Chapman S; Leevy M; Upendran A; Kannan R
    Sci Rep; 2016 Aug; 6():30245. PubMed ID: 27530552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug.
    Beh CW; Seow WY; Wang Y; Zhang Y; Ong ZY; Ee PL; Yang YY
    Biomacromolecules; 2009 Jan; 10(1):41-8. PubMed ID: 19072631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation, Characterization, and In Vitro Evaluation of Lipidoid-Polymer Hybrid Nanoparticles for siRNA Delivery to the Cytosol.
    Thanki K; Zeng X; Foged C
    Methods Mol Biol; 2019; 1943():141-152. PubMed ID: 30838614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silica nanoparticles and polyethyleneimine (PEI)-mediated functionalization: a new method of PEI covalent attachment for siRNA delivery applications.
    Buchman YK; Lellouche E; Zigdon S; Bechor M; Michaeli S; Lellouche JP
    Bioconjug Chem; 2013 Dec; 24(12):2076-87. PubMed ID: 24180511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD44 targeted delivery of siRNA by using HA-decorated nanotechnologies for KRAS silencing in cancer treatment.
    Tirella A; Kloc-Muniak K; Good L; Ridden J; Ashford M; Puri S; Tirelli N
    Int J Pharm; 2019 Apr; 561():114-123. PubMed ID: 30822503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced intracellular siRNA delivery using bioreducible lipid-like nanoparticles.
    Wang M; Alberti K; Varone A; Pouli D; Georgakoudi I; Xu Q
    Adv Healthc Mater; 2014 Sep; 3(9):1398-403. PubMed ID: 24574196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cationic bovine serum albumin based self-assembled nanoparticles as siRNA delivery vector for treating lung metastatic cancer.
    Han J; Wang Q; Zhang Z; Gong T; Sun X
    Small; 2014 Feb; 10(3):524-35. PubMed ID: 24106138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic silencing of KRAS using systemically delivered siRNAs.
    Pecot CV; Wu SY; Bellister S; Filant J; Rupaimoole R; Hisamatsu T; Bhattacharya R; Maharaj A; Azam S; Rodriguez-Aguayo C; Nagaraja AS; Morelli MP; Gharpure KM; Waugh TA; Gonzalez-Villasana V; Zand B; Dalton HJ; Kopetz S; Lopez-Berestein G; Ellis LM; Sood AK
    Mol Cancer Ther; 2014 Dec; 13(12):2876-85. PubMed ID: 25281617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. F127/Calcium phosphate hybrid nanoparticles: a promising vector for improving siRNA delivery and gene silencing.
    Qin L; Sun Y; Liu P; Wang Q; Han B; Duan Y
    J Biomater Sci Polym Ed; 2013; 24(15):1757-66. PubMed ID: 23746331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel targeted siRNA-loaded hybrid nanoparticles: preparation, characterization and in vitro evaluation.
    Dim N; Perepelyuk M; Gomes O; Thangavel C; Liu Y; Den R; Lakshmikuttyamma A; Shoyele SA
    J Nanobiotechnology; 2015 Sep; 13():61. PubMed ID: 26410728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gold nanoparticle-siRNA mediated oncogene knockdown at RNA and protein level, with associated gene effects.
    Child HW; Hernandez Y; Conde J; Mullin M; Baptista P; de la Fuente JM; Berry CC
    Nanomedicine (Lond); 2015; 10(16):2513-25. PubMed ID: 26302331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PEGylated carboxymethyl chitosan/calcium phosphate hybrid anionic nanoparticles mediated hTERT siRNA delivery for anticancer therapy.
    Xie Y; Qiao H; Su Z; Chen M; Ping Q; Sun M
    Biomaterials; 2014 Sep; 35(27):7978-91. PubMed ID: 24939077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery.
    Lee JH; Lee K; Moon SH; Lee Y; Park TG; Cheon J
    Angew Chem Int Ed Engl; 2009; 48(23):4174-9. PubMed ID: 19408274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of lung cancer multidrug resistance by pH-responsive micelleplexes mediating co-delivery of siRNA and paclitaxel.
    Yu H; Xu Z; Chen X; Xu L; Yin Q; Zhang Z; Li Y
    Macromol Biosci; 2014 Jan; 14(1):100-9. PubMed ID: 23966347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymer Based Gene Silencing: In Vitro Delivery of SiRNA.
    Carlos MI; Schätzlein A; Uchegbu I
    Methods Mol Biol; 2016; 1445():149-57. PubMed ID: 27436317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles.
    Carmona S; Jorgensen MR; Kolli S; Crowther C; Salazar FH; Marion PL; Fujino M; Natori Y; Thanou M; Arbuthnot P; Miller AD
    Mol Pharm; 2009; 6(3):706-17. PubMed ID: 19159285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.